Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Summers Laboratories has developed a non-pesticide treatment for head lice. Lice Asphyxiator (L.A.) works by mechanically blocking the respiratory spiracles of the head lice, therefore causing a quick-acting suffocation that will not result in the development of resistance.
The objectives of this open label study are to evaluate the efficacy and safety of home use of two 10-minute treatments of 5% L.A. (applied one week apart).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 5% Lice Asphyxiator lotion - Summers Laboratories, Inc. | Drug |
Inclusion Criteria:
Males and females 6 months of age or older.
Have an active infestation with Pediculus capitis, the human head louse, with at least three live lice at baseline, or treatment failure with any live lice from Protocol SU-01-2005 or Protocol SU-02-2005.
Agree not to use any other pediculicides or medicated hair grooming products during the duration of the study.
Be healthy, non-febrile, and not suffering from an infection likely to require antibiotic therapy during the study period.
Subject or guardian is able to understand the new HIPAA regulations and sign the HIPAA form.
Subject or guardian has read, understood, and signed appropriate informed consent in English. If English is not the primary language, the information about the study must be explained in their language and a copy of the informed consent must be in that language.
Subject is willing to participate in the study, and abide by the protocol requirements.
-
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Terri Meinking | Global Health Association of Miami | Principal Investigator |
| Anne Lucky, Dr. | Dermatology Research Associates | Principal Investigator |
| Jon Thomas, Dr. | Alegent Health | Principal Investigator |
| E.A. Clark, Dr. | Diagnostic Clinic of Longview, Tx | Principal Investigator |
| Peter E Silas, Dr. | Advanced Clinical Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Global Health Associates of Miami 7800, SW 57 Avenue, Suite 219E | Miami | Florida | 33143 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20199404 | Derived | Meinking TL, Villar ME, Vicaria M, Eyerdam DH, Paquet D, Mertz-Rivera K, Rivera HF, Hiriart J, Reyna S. The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). Pediatr Dermatol. 2010 Jan-Feb;27(1):19-24. doi: 10.1111/j.1525-1470.2009.01059.x. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Alegent Health, Harmony Street, 2nd Floor |
| Council Bluffs |
| Iowa |
| 51503-3147 |
| United States |
| Dermatology Research Associates 7691 Five Mile Road, Suite 312 | Cincinnati | Ohio | 45230 | United States |
| Diagnostic Clinic of Longview, TX 707 Hollybrook Drive | Longview | Texas | 75605 | United States |
| Wee Care Pediatrics, 1580 West Antelope Drive, Suite 100 | Layton | Utah | 84041 | United States |